Liquidia (NASDAQ:LQDA) Director Raman Singh Sells 8,468 Shares

by · The Cerbat Gem

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) Director Raman Singh sold 8,468 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $66.16, for a total value of $560,242.88. Following the sale, the director directly owned 44,637 shares of the company’s stock, valued at $2,953,183.92. This represents a 15.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Raman Singh also recently made the following trade(s):

  • On Friday, September 11th, Raman Singh sold 9,024 shares of Liquidia stock. The shares were sold at an average price of $68.62, for a total value of $619,226.88.

Liquidia Stock Up 0.6%

LQDA stock opened at $65.72 on Wednesday. The firm has a market capitalization of $5.88 billion, a PE ratio of 47.97 and a beta of 0.53. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. Liquidia Corporation has a twelve month low of $21.15 and a twelve month high of $93.61. The stock’s 50 day moving average is $76.88 and its 200-day moving average is $59.93.

Liquidia (NASDAQ:LQDA – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). The company had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The company’s quarterly revenue was up 1842.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.49) EPS. Sell-side analysts expect that Liquidia Corporation will post 2.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Lifesci Capital lowered shares of Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 target price for the company. in a research note on Wednesday, August 12th. HC Wainwright set a $36.00 price target on shares of Liquidia in a research report on Friday, July 24th. Piper Sandler set a $129.00 price target on shares of Liquidia in a report on Friday, July 24th. Wells Fargo & Company boosted their price target on shares of Liquidia from $62.00 to $108.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Finally, Oppenheimer set a $75.00 price objective on shares of Liquidia in a research report on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Liquidia currently has an average rating of “Hold” and an average price target of $98.08.

Read Our Latest Stock Analysis on Liquidia

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. WINTON GROUP Ltd bought a new position in Liquidia in the 2nd quarter valued at $335,000. Arizona State Retirement System raised its stake in shares of Liquidia by 5.4% during the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after purchasing an additional 900 shares during the period. Nykredit A S bought a new stake in shares of Liquidia during the 2nd quarter worth $177,000. Corient Private Wealth LP purchased a new position in shares of Liquidia in the 2nd quarter worth about $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Liquidia in the 2nd quarter worth about $1,236,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious cardiopulmonary conditions, including pulmonary arterial hypertension (PAH). The company is headquartered in Research Triangle Park, North Carolina, and serves healthcare providers and patients primarily in the United States.

Liquidia’s lead product is Yutrepia, an inhaled formulation of treprostinil designed for the treatment of PAH. The company has also developed treprostinil injection products and is pursuing additional therapies for rare cardiopulmonary diseases.

See Also